Drugs such as GLP-1 receptor agonistsincluding semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro)are now household names, praised for their ability to reduce appetite, regulate blood sugar, and promote sustained weight loss
Hormonal IUDs and Their Impact on Menstrual Cycles If you have a hormonal IUD, such as Mirena or Kyleena, you may already know that these devices release a small amount of progestin, a hormone that helps prevent pregnancy
Article 7 mins Why Organizations Need a Robust Directors and Officers Risk Program A variety of growing risks, including shareholder derivative actions, an evolving regulatory environment and bankruptcy filings, are why public and private organizations must protect their corporate directors and officers
We are so happy to be your trusted partner on this journey
Kidney: Patients with kidney disorders should use cautiously under medical supervision
The company also announced full enrolment in the LIBERATE-1 study, which was achieved in just four weeks after enrolment of the first subject, signalling early potential interest for this six-month, subdermal GLP-1 implant and reaffirming previous estimates that top-line results should be available in mid-2025